Compare CTVA & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTVA | NTRA |
|---|---|---|
| Founded | 1802 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.6B | 47.4B |
| IPO Year | 2018 | 2015 |
| Metric | CTVA | NTRA |
|---|---|---|
| Price | $78.47 | $411.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 15 |
| Target Price | $84.13 | ★ $259.07 |
| AVG Volume (30 Days) | ★ 3.3M | 1.2M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | ★ 23.08 | 0.65 |
| EPS | ★ 2.80 | N/A |
| Revenue | ★ $17,401,000,000.00 | $210,939,000.00 |
| Revenue This Year | $6.09 | $18.08 |
| Revenue Next Year | $3.28 | $19.65 |
| P/E Ratio | $28.38 | ★ N/A |
| Revenue Growth | ★ 2.92 | N/A |
| 52 Week Low | $60.54 | $157.43 |
| 52 Week High | $90.97 | $412.93 |
| Indicator | CTVA | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 38.59 | 83.65 |
| Support Level | $78.56 | $187.64 |
| Resistance Level | $81.07 | N/A |
| Average True Range (ATR) | 2.43 | 13.27 |
| MACD | -0.65 | 5.99 |
| Stochastic Oscillator | 11.69 | 95.85 |
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva plans to spin off its seeds business in late 2026. The seeds business will be named Vylor, while the crop protection business will retain the Corteva name and be a pure-play crop protection company following the divestiture. Corteva operates globally, but around half of revenue comes from North America.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.